Full-Time

Associate Director

Data Management

Confirmed live in the last 24 hours

Kymera Therapeutics

Kymera Therapeutics

201-500 employees

Develops targeted protein degradation therapies

Biotechnology
Healthcare

Senior, Expert

Belmont, MA, USA

Hybrid work model with a minimum of 3 days/week in the office.

Category
Data Management
Data & Analytics
Requirements
  • 10+ years’ experience in clinical data management in biotechnology or pharmaceutical industry, with outsourced CRO oversight experience
  • 7+ years managing vendor relationships/partnerships in a global environment.
  • Must have advanced knowledge of Data Management processes and systems
  • Solid understanding of CDISC standards required
  • Data Visualization Tool experience preferred.
  • Experience using standardized medical terminology, including but limited too MedDRA and WHODrug.
  • Excellent interpersonal, communication, and organizational skills with the ability to work independently and in a study team environment.
Responsibilities
  • Act as Lead Data Manager, overseeing all deliverables of activities outsourced to DM CRO for multiple studies
  • Interact and manage relationships with other functional areas to ensure high quality data management activities
  • Oversight of data collection tools (EDC, DTAs, EDC integrations) and essential documents (DMP, UAT Documents, data edit specifications, annotated case books and data entry guidelines)
  • Participate in User Acceptance Testing Activities for the applicable Data Collection Tools
  • Perform Quality Control for the data completeness and accuracy.
  • Participate in and support data cleaning, query generation and resolution and review of medical coding as needed.
  • Responsible for adhering to the Data Management timelines and budget.
  • Provide technical expertise to help in the use of technologies for Data Management and the clinical study team.
  • Contribute to the development of lessons learned and best practices as well as help develop SOPs and internal working procedures and process improvement initiatives.
  • Contribute to the establishment of systems and tools to help ensure clinical data security and integrity.
  • Contribute to the process to identify, evaluate and select external business partners and technology vendors

Kymera Therapeutics develops treatments by targeting and breaking down specific proteins that contribute to diseases, particularly cancer and immune disorders. Their main technology, the Pegasus Platform, enables them to identify these harmful proteins and create drug candidates aimed at effectively treating various conditions. Unlike many competitors, Kymera focuses on targeted protein degradation, which can lead to more precise therapies. The company's goal is to create next-generation medicines that address unmet medical needs, supported by partnerships with organizations like Sanofi to enhance their research and development efforts.

Company Stage

IPO

Total Funding

$191.6M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

16%
Simplify Jobs

Simplify's Take

What believers are saying

  • Kymera's recent $275 million public offering provides substantial capital to advance their clinical programs and expand their pipeline.
  • The FDA Fast Track designation for KT-333 could accelerate its development and bring it to market faster, benefiting patients with relapsed/refractory lymphomas.
  • Positive data from ongoing cancer drug trials and the unveiling of KT-294 highlight Kymera's potential for significant breakthroughs in oncology and immunology.

What critics are saying

  • The high costs and long timelines associated with biopharmaceutical R&D could strain Kymera's financial resources despite recent funding.
  • Dependence on partnerships, such as with Sanofi, introduces risks related to collaboration dynamics and milestone achievements.

What makes Kymera Therapeutics unique

  • Kymera Therapeutics leverages its proprietary Pegasus Platform for targeted protein degradation, setting it apart from traditional drug development approaches.
  • Their strategic partnership with Sanofi underscores their credibility and enhances their research capabilities, unlike smaller biotech firms with limited collaborations.
  • Kymera's focus on developing first-in-class therapies for cancer and immune disorders positions them uniquely in the biopharmaceutical market.

Help us improve and share your feedback! Did you find this helpful?